ASLAN Pharmaceuticals Announces Topline Results From TreeTopp Global Pivotal Study of Varlitinib in Biliary Tract Cancer

NEXT STORY
REDUCE-IT® USA Results, in Prespecified Subgroup Analyses of Landmark REDUCE-IT Global Study, Showed Robust Cardiovascular Risk Reductions Across a Variety of Study Endpoints, Including Cardiovascular Death and All-Cause Mortality
PREV STORY
Chi-Med Announces NDA Acceptance in China for Surufatinib in Non-Pancreatic Neuroendocrine Tumors
Subscribe to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Medtronic Announces Preliminary PRODIGY Results: a Global Study to Identify Patients at High Risk for Opioid-Induced Respiratory Compromise

author_avatar
NASDAQ Market News

Reneo Pharmaceuticals Appoints Eric Dube, Ph.D. to its Board of Directors

author_avatar
NASDAQ Market News

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2019 Financial Results and Provides Business Update

author_avatar
NASDAQ Market News